SCHEMBL3213935

SCHEMBL3213935

CC12CCCC(C1)C2(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTDSP1 Q9GZU7 3/20 0.34
APOBEC3A P31941 2/20 0.34
APOBEC3G Q9HC16 2/20 0.34
SIGMAR1 Q99720 8/20 0.34
CHRNB2 P17787 4/20 0.31
CHRNB4 P30926 4/20 0.31
CHRNA3 P32297 4/20 0.31
CHRNA7 P36544 4/20 0.31
CHRNA4 P43681 4/20 0.31
CHRNA1 P02708 3/20 0.31
CHRNG P07510 3/20 0.31
CHRNB1 P11230 3/20 0.31
CHRND Q07001 3/20 0.31
LMNA P02545 2/20 0.31
CYP3A4 P08684 1/20 0.31
PKM P14618 1/20 0.31
NFKB1 P19838 1/20 0.31
CYP2C19 P33261 1/20 0.31
THPO P40225 1/20 0.31
CHRNE Q04844 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3213927 1.00 CTDSP1 (0.34) CTDSP1APOBEC3AAPOBEC3GSIGMAR1CHRNB2
SCHEMBL1024401 0.83
SCHEMBL23967319 0.79 CTDSP1 (0.43) CTDSP1APOBEC3AAPOBEC3GSIGMAR1LMNA
Methyl Alcohol SCHEMBL1155257 0.79 CTDSP1 (0.43) CTDSP1APOBEC3AAPOBEC3GSIGMAR1CHRNB2
SCHEMBL9951680 0.73
Acetic Acid SCHEMBL189531 0.72 CTDSP1 (0.38) CTDSP1APOBEC3AAPOBEC3GSIGMAR1LMNA
SCHEMBL6581138 0.70 SIGMAR1 (0.41) CTDSP1APOBEC3AAPOBEC3GSIGMAR1LMNA
SCHEMBL10444957 0.70 CTDSP1 (0.37) CTDSP1APOBEC3AAPOBEC3GSIGMAR1LMNA
SCHEMBL15476357 0.70 MEN1 (0.30) LMNA
SCHEMBL16779993 0.70 CTDSP1 (0.36) CTDSP1APOBEC3AAPOBEC3GSIGMAR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2104497-B1 SULFAMIDE DERIVATIVES AS TAFIA INHIBITORS SANOFI SA (FR) 2015-02-25 EP claimed
US-8389764-B2 Urea and sulfamide derivatives as inhibitors of TAFIa SANOFI (FR) 2013-03-05 US claimed
US-20100035930-A1 UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa SANOFI-AVENTIS (FR) 2010-02-11 US claimed
CN-102786837-B Uv-curing type ink jet compositions and printed article 精工爱普生株式会社 2016-12-07 CN disclosed
CN-105965881-A Three-dimensional modeling apparatus and three-dimensional object manufacturing method 精工爱普生株式会社 2016-09-28 CN disclosed
CN-103242702-B Uv-curing type ink jet compositions and record thing 精工爱普生株式会社 2016-07-13 CN disclosed
CN-104924609-A Apparatus for producing three-dimensional structure, three-dimensional structure and method of producing three-dimensional structure SEIKO EPSON CORP 2015-09-23 CN disclosed
CN-104908317-A Three-dimensional structure manufacturing apparatus, manufacturing method of three-dimensional structure, and three-dimensional structure SEIKO EPSON CORP 2015-09-16 CN disclosed
CN-104908318-A Manufacturing method of three-dimensional structure, three-dimensional structure manufacturing apparatus, and three-dimensional structure SEIKO EPSON CORP 2015-09-16 CN disclosed
CN-104859146-A Three dimensional mold object manufacturing apparatus, method for manufacturing three dimensional mold object, and three dimensional mold object SEIKO EPSON CORP 2015-08-26 CN disclosed
CN-104842555-A Apparatus for manufacturing three-dimensional shaped object, method of manufacturing three-dimensional shaped object, and three-dimensional shaped object SEIKO EPSON CORP 2015-08-19 CN disclosed
EP-2104497-B1 SULFAMIDE DERIVATIVES AS TAFIA INHIBITORS SANOFI SA (FR) 2015-02-25 EP disclosed
US-8389764-B2 Urea and sulfamide derivatives as inhibitors of TAFIa SANOFI (FR) 2013-03-05 US disclosed
US-20100035930-A1 UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa SANOFI-AVENTIS (FR) 2010-02-11 US disclosed
EP-2104497-A2 UREA AND SULFAMIDE DERIVATIVES AS TAFIA INHIBITORS Sanofi-Aventis (FR) 2009-09-30 EP disclosed
WO-2008067909-A2 UREA AND SULFAMIDE DERIVATIVES AS TAFIA INHIBITORS SANOFI-AVENTIS (FR) 2008-06-12 WO disclosed
CN-1713787-A Organic electroluminescent device, method for producing the same, and electronic apparatus SEIKO EPSON CORP (JP) 2005-12-28 CN disclosed
US-5378691-A Amino acid derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1995-01-03 US disclosed
EP-0418696-A2 Derivatives of aminoacids MERCK PATENT GmbH (DE) 1991-03-27 EP disclosed
CN-1037155-A Amino acid derivative MERCK PATENT GMBH (DE) 1989-11-15 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035930-A1 UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa TFPI, TFPI2, SERPINE1 CTDSP1 1124/4885APOBEC3A 1499/4885APOBEC3G 1727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.